Isabella Fraschilla

Isabella Fraschilla

Auto-generated profile, based on publicly available information

Isabella Fraschilla

Center for the Study of Inflammatory Bowel Disease, Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital Research Institute, Boston, MA 02114, USA; Harvard Medical School, Boston, MA 02115, USA; Program in Immunology, Harvard Medical School, Boston, MA 02115, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2022 in Cell
Verified
Journal Article
Closed access
HAHajera Amatullah
Hajera Amatullah
IFIsabella Fraschilla
Isabella Fraschilla
SDSreehaas Digumarthi
Sreehaas Digumarthi
JHJulie Huang
Julie Huang
FAFatemeh Adiliaghdam
Fatemeh Adiliaghdam
KJKate L. Jeffrey
Kate L. Jeffrey

30 March 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
IFIsabella Fraschilla
Isabella Fraschilla
HAHajera Amatullah
Hajera Amatullah
RRRaza-Ur Rahman
Raza-Ur Rahman
KJKate L. Jeffrey
Kate L. Jeffrey
Inflammatory bowel disease (IBD) is driven by host genetics and environmental factors, including commensal microorganisms. Epigenetics facilitate integration of environmental cues for transcriptional output. However, evidence of epigenetic dysregulation directly causing host-commensal dysbiosis and IBD is lacking. Speckled Protein 140 (SP140) is an immune-restricted chromatin ‘reader’ with homology to Autoimmune Regulator (AIRE). SP140 mutations associate with three immune diseases: Crohn’s disease (CD), multiple sclerosis (MS) and chronic lymphocytic leukemia (CLL), but disease-causing mechanisms remain undefined. Here we identify a critical immune-intrinsic role for SP140 in preventing expansion of inflammatory Proteobacteria, including Helicobacter in mice and Enterobacteriaceae in humans. Mice harboring altered microbiota due to hematopoietic Sp140 deficiency exhibited severe colitis which was transmissible upon co-housing and ameliorated with antibiotics. SP140 was critical for calibration of macrophage microbicidal responses required for normal host-commensal crosstalk and elimination of invasive pathogens. Mutations within this epigenetic reader may constitute a predisposing event in human diseases provoked by the microbiome, such as IBD and MS.

15 October 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
YLYisha Liang
Yisha Liang
IEIsabella R. Evavold
Isabella R. Evavold
SPSepideh Parvanian
Sepideh Parvanian
MHMakiko Hayashi
Makiko Hayashi
EGEmerson Glassey
Emerson Glassey
CECharles L. Evavold
Charles L. Evavold
Pyroptosis is a lytic form of cell death executed by gasdermin pores. Through a CRISPR screen to uncover macrophage genes required for gasdermin D (GSDMD) pore activity, we identify the endosome adaptor Rabgef1 as a positive regulator of pore formation. Rabgef1 deficiency preserves NT-GSDMD membrane binding but prevents NT-GSDMD oligomerization and lytic death. Mechanistic analyses revealed that Rabgef1 deficiency is associated with an overabundance of cholesterol in the plasma membrane. Cholesterol depletion or redistribution through multiple approaches restores GSDMD oligomerization and pyroptosis. The Rabgef1-mediated control of membrane cholesterol and pore formation was found to be a general regulator of the gasdermin family. In cancer cells, organoids, and tumors, cholesterol reduction sensitizes resistant cells to GSDME pyroptosis driven by synthetic mRNAs, chemogenetic induction, and chemotherapy treatment. These results establish membrane cholesterol content as an endogenous checkpoint for gasdermin-mediated pyroptotic cell death during the execution phase, with implications for metabolic disease and cancer immunotherapy.